Surgical treatment of hepatocellular carcinoma  by Belghiti, Jacques & Kianmanesh, Reza
Surgical treatment of hepatocellular carcinoma
JACQUES BELGHITI & REZA KIANMANESH
Department of Digestive Surgery and Transplantation, Beaujon Hospital, Clichy, France Assistance Publique-Hoˆpitaux de
Paris, France
Abstract
Surgery for hepatocellular carcinoma (HCC) includes partial liver resection (LR) and liver transplantation (LT). Although
LT represents the most efficient treatment in patients with small HCC, 530% of patients are eligible for LT because of
restrictive criteria (one nodule 55 cm or two to three nodules 53 cm without macroscopic vascular invasion), graft
unavailability and the high cost of the procedure. For large HCC, LR remains the only potential curative treatment. LR is now
safer, with a low rate of mortality. Selective preoperative morphological assessment, preoperative use of portal vein emboli-
zation for increasing future remnant liver volume and the improvement of surgical techniques such as the use of intermittent
clamping and anterior approach are factors that improve the safety and tolerance of LR. In patients with small HCCs and a
preserved liver function (Child-Pugh grade A), good long-term survival can be achieved after anatomical resection that
removes the tumor(s) and its portal vein territory. These good results of LR for small HCC and the increasing duration of the
waiting list for candidates of LT have renewed the place of LR as a bridge treatment before LT.
Key words: Hepatocellular carcinoma, portal vein embolization, liver resection, anatomical liver resection, anterior approach,
liver transplantation
Introduction
Surgery, including liver transplantation (LT), remains
the most efficient treatment of patients with hepato-
cellular carcinoma (HCC). However, 530% of
patients with HCC are eligible for surgery, mainly
because of the multiplicity of the lesions which often
occurs on a background of chronic liver disease [1–3].
Over the past 10 years, there has been considerable
progress in the diagnosis and surgical treatment of
HCC. The tumors are more often identified at an early
stage, in particular through the screening of high-risk
patients [4–7]. Surgery is safer, with an acceptable
overall mortality rate in cirrhotic patients (55%); also,
good long-term survival, up to450%, is achieved after
adequate anatomical resections [8,9]. Partial resection
is associated with a high incidence of tumor recurrence,
mainly due to the presence of the chronic underlying
liver disease which is a preneoplastic state [3,10].
Therefore, because LT removes the tumor(s) and the
preneoplastic underlying chronic liver disease, LT
appears to be the treatment of choice for small HCCs
[2,11]. However, to avoid tumor recurrence, LT
indications for HCC are restrictive and the limited
availability of grafts and the cost of the LT
represent the main potential limiting factors for its
development [12].
Partial liver resection of HCC
HCC without chronic liver disease
In the vast majority of cases, HCC develops in the
setting of cirrhosis, but 5–15% of patients have no
underlying chronic liver disease [13,14]. Usually, the
etiology of HCC developed in normal liver or minimal
fibrosis is undetermined, but in some cases a chronic
hepatitis B virus infection or hemochromatosis are
present. Fibrolamellar carcinoma, which frequently
occurs in patients with normal liver, represents a
variant of HCC with specific pathological and clinical
features [13]. The tumor is hypervascularized with
eosinophilic cells surrounded by a dense fibrous
stroma. The tumors are frequently observed in the
western hemisphere, in white females at a younger age
(20–40 years), more often located in the left liver with
positive lymph nodes, and alfa-fetoprotein (AFP) is
rarely elevated [15,16].
HCC tumors in patients with normal liver are often
large (410 cm) and diagnosed when tumors are
symptomatic [17–19]. The only curative treatment is
major hepatectomy, which is often well tolerated in the
absence of underlying liver disease and the good
regenerative capacity of the remnant liver. The long-
term results of resection of HCC without chronic liver
disease are much better than in patients with cirrhosis,
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with disease-free 5-year survival rates as high as 50%
[20,21]. These favorable results observed in both
fibrolamellar and nonfibrolamellar HCC variants
suggest that the absence of underlying liver disease is a
major factor in short- and long-term prognosis [3,20].
HCC with chronic liver disease
The selection of patients with HCC associated with
cirrhosis includes two main principles: surgery should
be curative, and it should not place the patient at risk of
operative death.
Indications for hepatectomy
In terms of tumor status, liver resection is usually
contraindicated when one of the following criteria is
present: (a) extrahepatic metastasis; (b) multiple and
bilobar tumors; (c) involvement of the main bile duct;
(d) presence of portal thrombus in the main portal vein
and/or the vena cava. Preoperative evaluation of
patients includes: ultrasonography (US) and thoraco-
abdominal helical multiphase contrast CT scan. The
accuracy of new generation CT scan with vascular
reconstruction has restricted the indication for angio-
graphy mainly to patients who are planned for pre-
operative transcutaneous arterial chemoembolization
(TACE). Despite the fact that TACE can in some
cases down-stage HCC, prospective trials have failed
to show any significant benefit of this treatment before
surgery [22–24].
Patients with HCC and tumor thrombus in the vena
cava or in the portal trunk have a poor prognosis [25].
This major vascular involvement is generally associated
with a large tumor for which no treatment could be
anticipated. It was shown that in a selected group of
patients with normal liver function and excellent
general status, extensive liver resection associated with
removal of the vascular thrombus can achieve favorable
survival results [25,26].
The role of hepatic resection for treatment of
multiple and bilobar HCCs is more controversial [27–
31]. Bilobar HCCs may represent advanced disease
with intrahepatic metastasis from one lobe to the other
or may represent multifocal HCCs. However, in some
selected patients with good liver function, the presence
of a small solitary lesion in the contralateral lobe cases
should not contraindicate the resection of the main
tumor, and in selected cases major hepatic resection
can be associated with wedge resection or local ablative
therapy (if the lesion is not superficial) [31,32].
Spontaneous rupture of HCC occurs in 5–15% of
patients [33–35]. This complication is observed parti-
cularly in patients with large superficial or protruding
tumors; it is associated with hypovolemic shock in less
than half of the patients [33,36]. In case of hemo-
peritoneum, transcutaneous arterial embolization
represents the best hemostasis procedure [34,35,37].
In patients with good liver function and single
tumor, rupture of HCC should not be regarded as a
contraindication to subsequent elective surgical treat-
ment [33,35,38].
A great proportion of patients with chronic liver
disease continue to present with advanced large
tumors. Large tumor size alone should not be con-
sidered as a contraindication for hepatic resection
[18,21,38,39]. It is proven that hepatic resection for
HCCs 410 cm in diameter without macroscopic
venous invasion is a safe and an effective option
[17,18,38]. However, the postoperative regenerative
process can be impaired in the presence of cirrhosis,
especially in the presence of small size of the future liver
remnant (FLR) (540% of the functional whole liver
volume) [40,41]. Therefore, the use of preoperative
portal vein embolization (PVE), the aim of which is to
induce hypertrophy of the FLR, was developed mainly
to improve the safety and tolerance in major liver
resections of both normal and injured liver paren-
chyma [42,43]. Previously, there were concerns about
the regenerative capacity of fibrotic or cirrhotic liver
parenchyma to hypertrophy after technically successful
PVE. Later, further studies showed that preoperative
PVE induces significant hypertrophy of the FLR even
in patients with chronic liver disease [40,44,45].
Furthermore, it was shown that preoperative PVE
inducing significant hypertrophy of the FLR could
improve the safety and tolerance of major liver re-
sections [41,46,47] in patients with chronic liver
disease (fibrosis and cirrhosis) [45]. Moreover, the
absence of hypertrophy of the nonembolized liver
(FLR) following technically successful PVE, became
a dynamic test and an indicator of the absence or
low capacity of the injured liver to regenerate and
therefore contraindicate major liver resection in these
patients [45].
Preoperative evaluation of liver functional reserve
In addition to the evaluation of tumor status and to
avoid postoperative liver failure, the preoperative liver
functional reserve assessment in cirrhotic patients is
critical for patient selection [8]. The overall incidence
of in-hospital death following liver resection for HCC
in studies published in the 1990s ranges between 1%
and 10% (Table I). In most studies, hospital mortality
was significantly higher in patients with liver cirrhosis
than in patients without cirrhosis. The predominant
cause of death in cirrhotic patients is liver failure, which
is mainly assessed by Child-Pugh classification [48],
which was originally designed for predicting the prog-
nosis of patients with portal hypertension undergoing
shunting operations. In the vast majority of western
centers, resection is contraindicated in grade C
cirrhotic patients and rarely limited resection is poss-
ible in grade B cirrhotic patients [20]. However, even in
grade A cirrhotic patients, with apparently normal liver
function, the risk of liver surgery is increased and more
sophisticated quantitative liver function tests have been
developed. The indocyanine green clearance (ICG)
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test seems the best single test for predicting mortality
after hepatectomy [49,50]. It is generally admitted that
ICG retention at 15 minutes of 515% identified
patients who could tolerate a major resection while
those with a value of420% could only tolerate limited
resection. Other factors predicting postoperative liver
failure are: (a) a volume of FLR estimated on CT
volumetry below 40% of the whole liver volume; (b) a
grade 4 fibrosis assessed by biopsy of the nontumorous
liver; (c) a high portal pressure assessed by grade 2 or 3
esophageal varices or measured by transjugular pres-
sure, and (d) the presence of a superimposed active
hepatitis assessed by preoperative elevated transami-
nase level more than twice normal [21,51–53].
Although those criteria were not commonly accepted,
there are strong arguments showing that patients with
either one of these criteria should not undergo a major
liver resection without preoperative PVE. In patients
with chronic liver disease, the degree of hypertrophy of
the future remnant liver after PVE is variable. It has
been suggested that selective TACE before PVE could
improve the rate of hypertrophy [54].
Extent of resection
The two main aims of hepatic resection, especially in
cirrhotic liver, seem to be opposite: one is to resect all
of the malignant tissue (tumor, satellite nodules, and
portal vein territory) with effective clearance; the other
is to leave enough nontumorous liver parenchyma to
prevent postoperative liver failure. This explains why
most centers perform limited resections for small
HCC, especially in patients with poor liver function.
The other argument for performing limited resections
is the pattern of postoperative recurrence, which results
in part from the development of new tumors in the
remnant liver [3,55–59]. However, the main risk
of limited resections is tumor recurrence by local
metastasis and particularly by tumor cell seeding in the
adjacent or distal liver segments through tumor portal
venous territory [8,60–62]. Anatomical resections
according to the architecture of the portal vein have the
potential to remove undetected cancerous foci (portal
vein metastases and satellite nodules) disseminated
from the primary gross tumor. The segmental or
subsegmental portal venous drainage areas of the
segment containing the tumor are identified by
intraoperative US [63]. Several studies demonstrated
that anatomical resections of small solitary HCC
achieve a significant better overall and disease-free
survival than limited resections, without increasing the
postoperative risk [60,62,64,65]. Therefore, when
possible, anatomical resection should be the treatment
of choice and considered as the reference surgical
treatment when comparing it to other treatments.
Moreover, when anatomical resection does not seem to
be possible, either because of the tumor location and/or
the degree of the liver function, other therapeutic
options such as LT and/or percutaneous treatments are
discussed.
Improvement of surgical resection
Twenty years ago, the mortality rate for hepatectomy
in cirrhotic patients was 410%. Substantial im-
provements in the surgical techniques of hepatic
resection in the past decade have resulted in a dramatic
decline in the operative mortality of hepatic resection
for HCC and allowed major resections in selected
cirrhotic patients (Table I).
Intermittent inflow occlusion. During liver resection,
reducing blood loss and transfusion are essential.
Several methods designed to limit bleeding from inflow
occlusion by portal triad clamping to complete vascular
Table I. Series of liver resection for HCC
Author, year
of publication
Study
period
Number
of patients
Cirrhosis
(%)
Diameter
55 cm (%)
In-hospital
mortality (%)
1 year
(%)
3 years
(%)
5 years
(%)
Results after curative surgical resection of HCC in Asian series
Nagasue, 1993 1980–90 229 77 75 11 80 51 26
Kawasaki, 1995 1990–93 112 68 83 2 92 79
Takenada, 1996 1985–93 280 52 2 88 70 50
Chen, 1997 1983–94 382 45 40 4 71 52 46
Makuuchi, 1998 1990–97 352 51 92 73 47
Poon, 2001 1989–94 136 50 29 13 68 47 36
1994–99 241 43 45 2.5 82 62 49
Shimozawa, 2004 1987–2001 135 71 100 2 95 73 55
Results after curative surgical resection of HCC in Western series
Franco, 1990 1983–88 72 100 60 7 68 51
Vauthey, 1995 1970–92 106 33 17 6 41
Nagorney, 1996 120 22 8 82 44 31
Llovet, 1999 1989–97 77 100 75 85 62 51
Fong, 1999 1991–98 154 65 24 4.5 81 54 37
Belghiti, 2002 1990–99 300 82 47 6 81 57 37
Ercolani, 2003 1983–99 224 100 81 3 83 63 42
Cha, 2003 1990–2001 164 40 4 79 51 40
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exclusion have been used [66]. The poor tolerance of
cirrhotic liver to warm ischemia led many authors to
contraindicate inflow occlusion in patients with
cirrhosis. However, it has been demonstrated that
intermittent inflow occlusion with periods of 15
minutes of clamping and 5 minutes of unclamping was
well tolerated [67]. This method, which minimizes
intraoperative bleeding, can be repeated safely for up to
90 minutes in cirrhotic patients with good liver func-
tion [64].
Anterior approach. When liver tumors are large, the use
of conventional techniques usually requires forceful
retraction and mobilization of the liver with possible
disadvantages including compression of both right and
left lobes and tumor dissemination. Interestingly, two
new techniques which do not require liver mobilization
are now available: (1) the anterior approach [68,69]
and (2) the ‘hanging maneuver’ [70]. In the anterior
approach, after hilar control of the vascular inflow, and
without prior mobilization of the right lobe containing
the tumor, the parenchymal plane is transected directly
from the anterior surface of the liver down to the
anterior surface of the inferior vena cava (IVC). After
anterior approach of the parenchyma, and the control
of all venous tributaries including the right hepatic
vein, the right lobe is mobilized and resected without
forceful retraction of both the right and left lobes. This
approach reduces the intraoperative blood loss, blood
transfusion, hospital death rate, pulmonary meta-
stases, and recurrence as compared with the con-
ventional approach [69]. The hanging maneuver is an
expansion of the anterior approach [70]. During this
maneuver, the liver is raised away from the anterior
surface of the IVC by a tape. The antero-posterior
parenchymal transection is then facilitated by an
upward traction on the tape (hanging the liver
parenchyma anteriorly) placed in front of the retro-
hepatic vena cava. This allows the surgeon to follow a
direct plane and it facilitates exposure and hemostasis
of the transected posterior parenchymal in front of the
IVC. This technique can be used both in patients with
normal or chronic liver disease and is contraindicated
for large tumors invading the vena cava and in the
presence of multiple adhesions between the prehepatic
liver parenchyma and the anterior surface of the
retrohepatic vena cava.
Recurrence following resection of HCC
The rate of recurrence following resection of HCC is
around 80% at 5 years [29,56,65,71–73]. The pre-
dominant cause of tumor recurrence is metachronous
carcinogenesis, as the precursor condition (cirrhosis)
persists after surgery [74]. Greater incidence of recur-
rence is associated with the following factors: presence
and severity of an underlying cirrhosis; presence of
multiple nodules; tumor of45 cm in diameter; lack of
a capsule; moderately or poorly differentiated HCC;
presence of daughter nodules; venous invasion; infil-
trating rather than expansive tumor; insufficient
cancer-free margin; and intraoperative blood trans-
fusion [65,72,73,75]. Thus, any neoadjuvant or
adjuvant therapy that can decrease or delay the inci-
dence of intrahepatic recurrence should be considered
after partial hepatectomy [1,76].
Although recurrence following resection of HCC is
associated with a poor outcome in most cases, there is
growing evidence that some patients will benefit from
more aggressive approaches, especially if the recur-
rence is limited to the liver [77–79]. Multimodality
therapy including TACE, percutaneous ablative
therapy, and re-resection could result in prolonged
survival with an overall 5-year survival rate of 20%
[30,71,73,80,81].
Results of liver resection
The largest report of resected patients comes from the
Liver Cancer Study Group in Japan, which has re-
ported 1-, 3-, 5-, and 10-year survival rates of 85%,
64%, 45%, and 21%, respectively, in 6785 cirrhotic
patients treated by hepatic resection between 1988 and
1999 [82]. Comparable results have been reported by
other groups worldwide without differences between
Western and Asian studies (Table I). Survival rates as
high as 60% at 5 years may be achieved in Child grade
A patients with well-encapsulated tumors of 42 cm
in diameter. Although 510% of patients fit these
selection criteria, such results, obtained in patients
with good liver function who underwent anatomical
resection, could be favorably compared with those of
liver transplantation [83,84].
Liver transplantation
LT is obviously the most attractive therapeutic option
for HCC because it removes both detectable and
undetectable tumor nodules together with the pre-
neoplastic lesions that are present in the cirrhotic
liver. In addition, it simultaneously treats the under-
lying cirrhosis and prevents the development of
Table II. Series of liver transplantations for HCC in cirrhotic
patients
Authors Year n
3-year
survival (%)
Iwatsuki 1991 105 40
Bismuth 1993 60 49
McPeake 1993 87 10
Mazzaferro 1996 48 84
Llovet 1998 58 74
Figueras 2000 85 74
Hemming 2001 112 63
Adam 2001 195 66
Roayaie 2002 43 58
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postoperative or distant complications associated with
portal hypertension and liver failure.
Three distinct periods of LT for HCC can be
identified (Table II). Before 1996, LT was initially
performed in patients in whom partial liver resection
could not be contemplated because of the high number
and/or large size of the tumors. The results of LT for
large unresectable tumors were disappointing, with a
high rate of recurrence within the first months or years
post-transplant [85]. After the publication of criteria
proposed by Mazzaferro et al. [11] from the Milan
group (i.e. a single nodule 55 cm or two or three
nodules each53 cm without vascular invasion) several
groups have published remarkable improved results.
Therefore, LT was considered as a first-line option for
patients with limited tumor(s) [11,86]. However,
during the most recent period various series showed a
significant decrease of long-term survival in patients
who underwent LT for HCC, with a high rate of re-
currence. It must be noted that the use of (nonspecific)
immunosuppressive treatments markedly accelerated
the course of recurrence. The decline of survival during
the last period could be related to two factors: the
increase in the waiting list and the extension of the size
criteria. Some authors considered the Milan criteria to
be too restrictive, they expanded the indications for LT
[87,88]. The increase in waiting time is associated with
tumor progression and especially development of
vascular invasion. Accordingly, strategies to increase
the donor pool and diminish the tumor progression
rate became a priority in many centers. In the United
States, the United Network for Organ Sharing
proposed a new system to allocate patients on the list
according to the MELD score [89]. This change gives a
priority to patients to minimize drop-out rates.
Additional organs might be used by accepting
marginal livers (advanced age or steatotic organs).
Living donor LT has emerged as the most feasible
alternative to cadaveric LT. It has been shown that the
benefits of living donor LT for early HCC compared
with cadaveric LT are reached in waiting times
exceeding 7 months [90]. The availability of living
donor LT has opened the potential for an expansion of
the criteria beyond those conventionally applied.
However, it can be anticipated that a massive extension
of the criteria for transplantation to patients with larger
tumors may significantly impair the results of trans-
plantation in general. Because the morbidity-mortality
of the donor is a major concern, it is highly question-
able to take a donor risk for an uncertain recipient
prognosis [91].
The tumor management while awaiting transplan-
tation includes several modalities such as percutaneous
radiofrequency ablation, TACE, and hepatic re-
section. The two nonsurgical treatments are widely
used, but their impact on survival is unproved. We have
demonstrated that surgical resection before LT does
not increase the surgical risk nor impair the survival
[83]. Therefore resection and transplantation could be
associated rather than opposed. Resection could be
used as a bridge to transplantation, especially for
tumors located in the upper part of the right liver,
which can be easily and completely removed through a
transthoracic incision [92]. Similarly, some superficial
tumors which are not easily accessible by a percuta-
neous approach could be resected through a laparo-
scopic approach. Such previous resection allows a
better selection of transplant candidates [83,84]. As a
matter of fact, markers other than size and number
have recently emerged as significant prognostic vari-
ables – such as differentiation and the presence of
satellite nodules. These factors can only be fully
ascertained upon the complete examination of the
resected specimen [83]. The strategy that combines
resection and transplantation opens a completely new
field of investigation and will certainly evolve with time
[72,83,84]. We are currently speeding up the trans-
plantation process if markers of early recurrence are
present in the resected specimen, whereas we tend to
consider resection as the first-line treatment in their
absence and perform transplantation as salvage once
recurrence occurs, as suggested by Poon et al. [72].
This latter option has been shown not to be associated
with a loss of chance in HBV patients (who are the most
frequent in Hong Kong) and we are currently investi-
gating whether the same holds true in HCV patients
(who predominate in the West and Japan).
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